{{medical}}
{{drugbox
| Verifiedfields = 
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = F41401512X| verifiedrevid = 408768857
| IUPAC_name = 4-methyl-''N''-[3-(4-methyl-1''H''-imidazol-1-yl)- 5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide
| image = Nilotinib2DACS.svg
| width = 300
| image2 = Nilotinib3Dan.gif
| width2 = 250
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 559260
| InChI = 1/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
| InChIKey = HHZIURLSWUIHRB-UHFFFAOYAR
| smiles = Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 255863
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HHZIURLSWUIHRB-UHFFFAOYSA-N
| CAS_number = 641571-10-0
| CAS_supplemental = (base)
| CAS_number_Ref = {{cascite|changed|??}}
| ATC_prefix = L01
| ATC_suffix = XE08
| PubChem = 644241
| DrugBank = 
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08953
| C = 28 | H = 22 | F = 3 | N = 7 | O = 1
| molecular_weight = 529.5245 g/mol
| bioavailability = 30%
| protein_bound = 98%
| metabolism = [[胆|胆]]
| elimination_half-life = 17 h
| excretion = 胆道
| pregnancy_AU =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US =  D
| pregnancy_category =  
| legal_AU =  <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA =  <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  POM
| legal_US =  Rx-only
| legal_status = 
| routes_of_administration = Oral
| licence_EU        =  Tasigna 
| licence_US        =  Nilotinib
}}
[[File:3CS9_Abl1_Nilotinib.png|250px]](藍色)的晶體結構]]

'''尼洛替尼/尼罗替尼'''（{{lang-en|Nilotinib}}），港澳稱為「尼洛替尼」，是由[[瑞士|瑞士]][[諾華公司|諾華公司]]研製銷售，治療[[慢性骨髓性白血病|慢性骨髓性白血病]]的第二代/新一代[[標靶藥物|標靶藥物]]。在一项I型临床试验中，尼洛替尼/尼罗替尼被发现，其也因其临床编号称之为'''AMN107'''。该药药效安全，并对治疗慢性骨髓性白血病/[[慢性粒细胞性白血病|慢性粒细胞性白血病]]患者服用[[伊马替尼|伊马替尼]]（{{lang-en|imatinib}}）而产生的抗药性有很好的疗效。<ref>{{cite journal | author = Kantarjian H ''et al.'' | title = Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL | journal = N Engl J Med | volume = 354 | issue = 24 | pages = 2542–51 | year = 2006 | pmid = 16775235 | doi = 10.1056/NEJMoa055104}}</ref>在一项研究调查中，92%的患者（已经出现抗药性或药效迟钝性）通过五个月的疗程而获得了正常的白细胞总量标准<ref>{{cite news|url=http://cws.huginonline.com/N/134323/PR/200606/1056533_5.html|title=Patients with treatment-resistant leukemia achieve high responses to Tasigna (nilotinib) in first published clinical trial results|date=2006-06-14|work=MediaReleases|publisher=[[Novartis|Novartis]]|accessdate=2009-08-04|archive-date=2011-07-09|archive-url=https://web.archive.org/web/20110709140521/http://cws.huginonline.com/N/134323/PR/200606/1056533_5.html|dead-url=no}}</ref>。是一种[[酪氨酸激酶抑制剂|酪氨酸激酶抑制剂]]，其含量主要抑制[[BCR-ABL|BCR-ABL]]<ref name="pmid16721371">{{cite journal |author=Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD |title=AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |journal=Br. J. Cancer |volume=94 |issue=12 |pages=1765–9 |pmid=16721371 |doi=10.1038/sj.bjc.6603170 |pmc=2361347|date=June 2006}}</ref>、[[CD117|KIT]]、[[Lck|LCK]]、EPHA3、EPHA8、DDR1、DDR2、PDGFRB、MAPK11、ZAK激酶等。2007年，該藥已被[[美國|美國]][[FDA|FDA]]批准用於治療慢性骨髓性白血病。及後於2009年, 被[[歐盟|歐盟]][[EMA|EMA]]批准治療慢性骨髓性白血病。於2011年,於香港得到批准發售。

== 使用==
此藥已在美国和欧盟注册为'''达希纳'''（{{lang-en|Tasigna}}），港澳稱為「尼洛替尼」，其主要用於針對治療慢性骨髓性白血病/[[慢性粒细胞性白血病|慢性粒细胞性白血病]]的一線口服標靶治療藥物。

此藥物分為150毫克及200毫克。

需每天服藥兩次，每次服藥須相隔12小時。
例如第一劑藥於早上十時服用,第二劑藥應在晚上十時服用。

需留意,用膳前兩小時之內及用膳後一小時內皆不宜服藥。接受尼洛替尼治療療程間，切勿進食西柚或飲用西柚汁。

== 醫療用途==
尼洛替尼是用於治療慢性骨髓性白血病/慢性髓細胞性白血病(CML)的一線口服標靶治療藥物。

==治療 ==
治療方案的演進:

90年代或以前，使用[[化療干擾素|化療干擾素]]及[[骨髓移植|骨髓移植]]

21世紀，加入標靶治療藥物 ([[酪氨酸激酶抑制劑|酪氨酸激酶抑制劑]] Tyrosine-Kinase Inhibitor, TKI)


最新《2013 歐洲白血病網絡(ELN)治療指引》指出<ref>Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; '''122'''(6): 872-84.</ref>：

*治療方案3個月, BCR-ABL 病變基因數量 ≤10% (MR1)

*治療方案6個月, BCR-ABL 病變基因數量 <1% (MR2)

*治療方案12個月, BCR-ABL 病變基因數量 ≤0.1% (MR3)

*BCR-ABL 病變基因數量 ≤0.0032% (即MR 4.5)為深層分子反應,基因達無法檢測(undetectable) 

臨床數據顯示,達MR4.5的患者,可使病情不會再惡化。

==臨床實驗結果==
ENESTnd研究指出新一代尼洛替尼與舊一代伊馬替尼相比<ref>Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; '''30'''(5): 1044–1054.</ref>:

*於三個月時達致BCR/ABL病變基因的≤10% ,接受尼洛替尼的病人有91%達標, 而接受伊馬替尼的病人有67%達標

*於12個月時達致BCR/ABL病變基因的≤0.1% , 接受尼洛替尼的病人有44%達標, 而接受伊馬替尼的病人有22%達標

*於60個月時達致BCR/ABL病變基因的≤0.0032% (即MR 4.5水平)的百分比 , 接受尼洛替尼的病人有54%達標, 而接受伊馬替尼的病人有31%達標

研究指出, 新一代尼洛替尼與舊一代伊馬替尼相比, 有更佳的醫療效果。

其他有關尼洛替尼一線治療的研究有ENEST1st，其顯示尼洛替尼能令病人迅速達成深度反應，12個月時累計21%病人獲得MR4.5，24個月時更達到39%，幾乎翻倍<ref>Hochhaus A, et al.Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016; '''30'''(1): 57-64.</ref>。更多研究有關二線尼洛替尼的有效性和安全性。ENESTcmr比較伊馬替尼服用2年後轉用尼洛替尼和繼續伊馬替尼的效果，結果顯示尼洛替尼達到MR4.5的中位時間是24個月，而伊馬替尼甚至在48個月時也未達到<ref>Hughes TP, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017; '''31''': 2529–31.</ref>。2101研究顯示，二線轉用尼洛替尼可令病人達到最佳治療反應<ref>Kantarjian HM, et al. Nilotinib is effective in patients with chronic myeloid  leukaemia  in  chronic  phase  after  imatinib  resistance  or  intolerance:  24-month follow-up results. Blood. 2011;'''117''':1141-45.</ref>；4年總體估計生存率達78%<ref>Giles FJ, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;'''27'''(1):107-112.</ref>。ENRICH研究顯示因低級數慢性不良事件而由伊馬替尼轉用尼洛替尼的病人，其中一半獲得了MR4.5，並且生活質素獲得了整體改善<ref>Cortes J, et al. Clin Lymphoma Myeloma Leuk. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. 2016; '''16'''(5): 286-296.</ref>。

TKI 治療獲得深度分子學反應持續超過2年的CML患者部分能夠獲得長期的無治療緩解（treatment free remission, TFR），即功能性治癒。最新的ENESTfreedom研究證實了這個觀點<ref>Ross DM, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018 Feb 22. [Epub ahead of print]. </ref>。

*尼洛替尼停藥96周後，48.9% (93/190)的病人仍處於TFR階段並維持MMR，還有88個病人維持MR4.5

*46.3%(88/190)病人由於失去MMR而重啟尼洛替尼治療，經過中位數為7周的治療後，98.9%(87/88)的病人重新獲得MMR

*與肌肉骨骼痛相關的不良事件的頻度於TFR的首48周內,與鞏固期比較(17%)出現上升（34%）,隨後在第二個48周內出現下降(9.0%)

*ENESTop研究則顯示，163名伊馬替尼治療失敗後接受二線尼洛替尼治療的病人，77.3% (126/163)達到了TFR的標準，58%與53%的病人分別在48周與96周時仍維持 TFR<ref> Mahon FX, et al.Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018 Feb 20. [Epub ahead of print]</ref>。

==参考文献==
{{reflist|2}}

== 參見 ==
*[[Bcr-Abl酪氨酸激酶抑制剂|Bcr-Abl酪氨酸激酶抑制剂]]（Bcr-Abl tyrosine-kinase inhibitor、Bcr-Abl TKI)）
*[[酪氨酸激酶抑制劑|酪氨酸激酶抑制劑]]
*[[ABL激酶結構域|ABL激酶結構域]]（ABL (gene)）

==外部連結==
* New drug information/Abbreviated [https://web.archive.org/web/20121111182229/http://oncozine.com/page/nilotinib-tasignar-novartis Scientific Narrative]
* [https://web.archive.org/web/20180920171612/http://api.ning.com/files/1Vb2ZikWq33ReAnTgPc3uSN6e9G*-Zsz6OOqaVFVGhQeGO7FKqz4SaWB*ih7Bn1EUHJSRRdZRfzRHzJKpfZ2aSqLhmzWr81e/Nilotinib_Tasigna.pdf Highlights of Prescription information Nilotinib] (August 2007) Novartis Pharmaceuticals Corporation (USA)
* [https://web.archive.org/web/20180920171619/http://api.ning.com/files/1Vb2ZikWq30nE*znmFUq-arh9O67ktOpYwnCqC166ZEnmNGgrFOEBY4K9vdG3jkGeJpBvhtY33eGDJHWuOaAgGFeIi0YMuuB/Nilotinib_WC500034394.pdf Summary of Product Characteristics Nilotinib] (November 2007) Novartis AG (Europe)

{{Extracellular chemotherapeutic agents}}
{{Growth factor receptor modulators}}

[[Category:罕用药|Category:罕用药]]
[[Category:非受体酪氨酸激酶抑制剂|Category:非受体酪氨酸激酶抑制剂]]
[[Category:咪唑|Category:咪唑]]
[[Category:苯酰替苯胺|Category:苯酰替苯胺]]
[[Category:嘧啶|Category:嘧啶]]
[[Category:吡啶|Category:吡啶]]
[[Category:三氟甲苯|Category:三氟甲苯]]